CoChat

Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Key Points: Ability to accurately attribute adverse events post–gene therapy is required to describe the benefit-risk of these novel treatments. A SCD patient developed myelodysplastic syndrome post-LentiGlobin treatment; we show how insertional oncogenesis was excluded as the cause.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019001330

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 162

Metadata

Authors
Hsieh, M. M., Bonner, M., Pierciey, F. J., Uchida, N., Rottman, J., Demopoulos, L., Schmidt, M., Kanter, J., Walters, M. C., Thompson, A. A., Asmal, M., & Tisdale, J. F.
Affiliations
  • National Institutes of Health (US)
  • Bluebird Bio (United States) (US)
  • GeneWerk GmbH, Heidelberg, Germany;
  • University of Alabama at Birmingham (US)
  • University of California, San Francisco (US)
  • Northwestern University (US)
Venue
Blood Advances
Published
2020-05-12
Volume
4
Issue
9
Pages
2058-2063
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3024470836
Cited by
152
References
32
Citations by year
2026: 14 · 2025: 24 · 2024: 25 · 2023: 35 · 2022: 29 · 2021: 23 · 2020: 2
FWCI
13.03
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
bluebird bio
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
myelodysplastic syndrome, sickle cell disease, gene therapy, lentiviral vectors, insertional oncogenesis, risk-benefit assessment
MeSH terms
Anemia, Sickle Cell, Humans, Myelodysplastic Syndromes, Genetic Therapy, Lentivirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. https://app.cochat.ai/papers/10.1182/bloodadvances.2019001330
The paper
Hsieh, M. M., Bonner, M., Pierciey, F. J., Uchida, N., Rottman, J., Demopoulos, L., Schmidt, M., Kanter, J., Walters, M. C., Thompson, A. A., Asmal, M., & Tisdale, J. F. (2020). Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Advances. https://doi.org/10.1182/bloodadvances.2019001330

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.